Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Immunodeficiency Diseases01:25

Immunodeficiency Diseases

2.0K
Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency...
2.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same authorSame journal

Infectious Complications of CD19-targeted Chimeric Antigen Receptor T-cell Therapy: a Multicenter Cohort Study.

Open forum infectious diseases·2026
Same author

Autoantigen-loaded Polymeric Microparticles associate with B cells and promote tolerogenic antigen presentation in a mouse model of experimental autoimmune encephalomyelitis.

Nature communications·2026
Same author

Ibrutinib plus venetoclax for patients with relapsed or refractory mantle cell lymphoma: an editorial on the phase 3 SYMPATICO trial.

AME clinical trials review·2026
Same author

Single-cell gain-of-function mapping reveals latent regulatory programs governing CD8<sup>+</sup> T cell fate.

Research square·2026
Same author

Real-world outcomes of bispecific antibody therapy after chimeric antigen receptor T-cell therapy in follicular lymphoma.

Blood cancer journal·2026
Same author

High-avidity cathepsin-G-specific CAR-T cells for the treatment of acute myeloid leukemia.

Blood·2026

Related Experiment Video

Updated: Jan 17, 2026

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
06:08

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

1.7K

Infectious Complications Following CD30 Chimeric Antigen Receptor T-cell Therapy in Adults.

Felicia Cao1, Yueling Xiu2, Michael Mohnasky3

  • 1Divisions of Hematology and Oncology, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.

Open Forum Infectious Diseases
|September 22, 2025
PubMed
Summary

Infections after CD30 CAR T-cell therapy for lymphomas are primarily viral and mild, mostly occurring within 28 days. This contrasts with CD19 CAR T-cell therapy, which sees more severe bacterial infections.

Keywords:
CAR T-cell therapycancerhematological malignanciesimmunocompromised hostinfections

More Related Videos

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

1.3K
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.7K

Related Experiment Videos

Last Updated: Jan 17, 2026

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
06:08

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

1.7K
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

1.3K
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.7K

Area of Science:

  • Oncology
  • Immunotherapy
  • Infectious Diseases

Background:

  • Chimeric antigen receptor T-cell (CAR-T) therapy is associated with infections, but data on non-CD19 CAR-T agents are limited.
  • CD30-targeted CAR T-cell therapy is a novel treatment for relapsed/refractory CD30+ lymphomas.

Purpose of the Study:

  • To characterize infectious complications following CD30 CAR T-cell therapy.
  • To compare infection rates and types between CD30 CAR T-cell and CD19 CAR T-cell therapy recipients.

Main Methods:

  • Retrospective analysis of 64 adult patients receiving anti-CD30 CAR T-cells for CD30+ lymphomas.
  • Assessment of microbiologically confirmed infections within one year post-infusion, calculating infection density and cumulative incidence.
  • Comparison with a concurrent cohort of 50 CD19 CAR-T recipients.

Main Results:

  • The infection density within one year post-CD30 CAR T-cell infusion was 0.131 per 100 patient-days.
  • A 1-year cumulative incidence of 32% for infections was observed, with most being mild and viral (predominantly respiratory viruses) within the first 28 days.
  • Bacterial infections were infrequent (4.9%) and less severe compared to the CD19 CAR-T cohort, where bacterial infections predominated.

Conclusions:

  • Infectious complications after CD30 CAR T-cell therapy are predominantly mild and viral, differing significantly from CD19 CAR T-cell therapy.
  • Findings suggest potential adjustments to antimicrobial prophylaxis strategies for patients undergoing CD30 CAR T-cell treatment.